CarreirasRelações com InvestidoresCOVID-19
  1. Home
  2. Laboratory Diagnostics
  3. Responder ao apelo para resolver a pandemia do COVID-19

Responder ao apelo para resolver a pandemia do COVID-19Por trás de cada profissional de laboratório, está o apoio de 53.000 Healthineers

A urgência e a complexidade da situação atual do COVID-19 continuam a crescer e os laboratórios desempenham um papel essencial. Os testes para SARS-CoV-2 não são a única necessidade no tratamento de pacientes com COVID-19. A triagem e a monitorização rápidas e precisas para a variedade de problemas de saúde que podem surgir através da doença COVID-19 também são necessárias.

SARS-CoV-2 virus rendering

The essential role of laboratory diagnostics in SARS-CoV-2 infection

We are committed to helping laboratorians navigate this new world, in order to help you provide the best care to patients in this challenging time. A new COVID-19 Laboratory Testing Guide provides timely, relevant content to support the extended role of laboratory diagnostics in managing COVID-19 patients:

  • Transmission and clinical classification
  • Course of patients at risk
  • Current recommendations for laboratory testing
  • Frequent laboratory abnormalities
  • Impact of patients with co-morbidities

At Siemens Healthineers, we are fully committed to supporting our partners throughout the healthcare system by helping them deliver high-value care to patients.

GALLERY: Infographics to learn about COVID-19 Testing

1/7
COVID-19 Testing Infographic 2020

Testing is key to reopening communities, businesses, and the economy

Combined testing to detect the virus and antibodies that may protect against it is essential to safely return employees to work.
COVID-19 Testing Infographic 2020
Total Assay Infographic lab version
Total Assay Infographic media version
COVID-19 infographic
CytokineStorm Infographic
Specificty Matters Infographic
Lab testing and frequent laboratory abnormalities in patients with COVID-19 infographic
1/7

Diagnostic testing for COVID-19

As a truly emergent human pathogen, a specific test for presence of the virus did not exist with the onset of cases, necessitating rapid development. Most current testing for infection relies on detection of the viral RNA using a reverse-transcription polymerase chain reaction (rtPCR). In addition, serology testing from a blood sample can identify antibody to the virus.1,2 These tests will likely prove extremely valuable for surveillance and could potentially provide assessment for immunity, as well as aiding identification of acute infection.

As availability and supplies for molecular testing for COVID-19 increase, testing turn-around times should improve, but remain contingent on sample collection, proper preanalytical handling (RNA is highly degradable), time to test result, and access to testing (point-of-care vs. lab-based).

Covid-19 employee story Frisch Group Shot

Read news and stories about diagnostics and COVID-19

Randy Q. Cron, MD, PhD

AACC Webinar: Cytokine Storm Syndrome and COVID-19

In this webinar, Dr. Randy Cron will discuss criteria for identifying Cytokine storm syndrome (CSS) in patients, complications, and available treatments which include glucocorticoids, but also targeted therapies that dampen pro-inflammatory cytokines like interleukin-1 (IL-1) and IL-6.

Speaker:
Randy Q. Cron, MD, PhD
University of Alabama at Birmingham

Prof. Mario Plebani and Prof. Shu Kui Wang

AACC Webinar: The Role of Laboratory Diagnostics in SARS-CoV-2 Infection and Related Comorbidities

Experiences and Population Management Strategies from Highly Affected Regions of China and Italy: Laboratory tests are vital throughout many clinical pathways, and this webinar describes how laboratory medicine can efficiently help combat the COVID-19 outbreak.

Speakers:
Prof. Mario Plebani
Professor of Clinical Biochemistry and Clinical Molecular Biology, University of Padova School of Medicine
Chief, Department of Laboratory Medicine, University Hospital, Padova, Italy

Prof. Shu Kui Wang
Vice Dean
Director of Central Laboratory
Nanjing First Hospital, Nanjing Medical University, Nanjing, China

COVID-19 Laboratory testing guide

COVID-19 Laboratory Testing Guide

Testing is critical to differentiate COVID-19 from other respiratory disease such as influenza or RSV (respiratory syncytial virus). Widespread testing will both inform a COVID-19 diagnosis and aid a greater understanding of disease prevalence, especially in infections that are asymptomatic.

COVID-19 Booklet - Patient brochure

COVID-19 Booklet

  • What are the symptoms of COVID-19?
  • How does COVID-19 progress?
  • How to test for, treat, and immunize
  • How are COVID-19 tests administered?
  • How to avoid spreading COVID-19
Siemens Healthineers coagulation abnormalities testing guide

Download eBook: Coagulation abnormalities in COVID-19 patients

As part of our commitment to labs and clinicians in the fight against the pandemic, we aim to keep you informed on current coagulation testing and monitoring recommendations in COVID-19 patients. Read our eBook for an overview on:

  • Thrombosis risk factors
  • ISTH-recommended coagulation testing algorithm
  • Leading recommendations for anticoagulation treatment
  • Relevant parameters for patient monitoring

AACC Webinar: Cytokine Storm Syndrome and COVID-19

In this webinar, Dr. Randy Cron will discuss criteria for identifying Cytokine storm syndrome (CSS) in patients, complications, and available treatments which include glucocorticoids, but also targeted therapies that dampen pro-inflammatory cytokines like interleukin-1 (IL-1) and IL-6.

Speaker:
Randy Q. Cron, MD, PhD
University of Alabama at Birmingham

The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.

1

Ehterinton, D. https://techcrunch.com/2020/03/27/the-fda-just-okayed-multiple-15-minute-blood-tests-to-screen-for-coronavirus-but-there-are-caveats/ (Accessed March 28, 2020)

2

Morris, A. https://www.azcentral.com/story/news/local/arizona-health/2020/03/28/university-arizona-working-tests-detect-covid-19-antibodies/5083093002/ (Accessed March 28, 2020)

*Under development. Not available for sale. Future availability cannot be guaranteed.

**CE-IVD labelled for diagnostic use in the EU. For research use only (RUO) in the U.S. Pursuing FDA emergency use authorization (EUA) and WHO emergency use listing (EUL).

***This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to regulatory requirements.